Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer.

Targeted therapy focused on highly expressed growth factor receptors is increasingly becoming popular for the treatment of lung cancer. Cancer cells exhibit higher levels of macropinocytosis than the normally quiescent non-cancerous cells, which can further be enhanced by growth factors. Here, we show the targeted enhancement of macropinocytosis in lung cancer cells for the delivery of the mitochondriotoxic peptide (KLAKLAK)2 using keratinocyte growth factor (KGF). We report the formation of a nanoparticle (NP) comprising of two chimeric fusion proteins, both fused to elastin-like polypeptide (ELP), (KLAKLAK)2-ELP and KGF-ELP. We show that (KLAKLAK)2-ELP nanoparticles are internalized via macropinocytosis and its internalization is facilitated by the interaction of the ELP domain with cell surface heparin sulfate proteoglycans. This internalization leads to mitochondrial depolarization and subsequent cell death. Also, we demonstrate that KGF-ELP selectively enhances macropinocytosis in cancer cells expressing high levels of the keratinocyte growth factor receptor (KGFR). Finally, the heterogeneous NPs consisting of (KLAKLAK)2-ELP and KGF-ELP selectively kill KGFR-expressing lung cancer cells. Hence, this multipronged approach of targeting highly active processes and receptors in cancer cells will be tremendously selective in the treatment of both early-stage and advanced-stage lung cancers, thereby improving patient's prognosis and survival rate.
AuthorsRaul Iglesias, Piyush Koria
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 32 Issue 12 Pg. 259 (Dec 2015) ISSN: 1559-131X [Electronic] United States
PMID26519258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Recombinant Fusion Proteins
  • Elastin
  • Receptor, Fibroblast Growth Factor, Type 2
  • keratinocyte growth factor receptor
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology)
  • Cell Line, Tumor
  • Drug Delivery Systems (methods)
  • Elastin
  • Humans
  • Lung Neoplasms (metabolism)
  • Pinocytosis (drug effects)
  • Receptor, Fibroblast Growth Factor, Type 2 (chemistry, pharmacokinetics, pharmacology)
  • Recombinant Fusion Proteins (chemistry, pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: